Growth hormone–releasing compounds do not all work the same way. Some stimulate the pituitary gland to release the body’s own growth hormone, while others directly replace growth hormone or imitate one of the natural signals controlling it.
The central pathway is:
Hypothalamic signals → pituitary GH release → liver and peripheral tissues → IGF‑1 production → downstream metabolic and growth effects
GH secretion is naturally pulsatile. It rises and falls throughout the day, with some of the largest pulses occurring during deep sleep. Because of this, one random GH measurement provides very limited information.
1. What is a secretagogue?
A secretagogue is a compound that causes a gland to release a hormone. Growth hormone secretagogues stimulate the pituitary gland to release endogenous—or internally produced—GH.
There are two major research classes.
GHRH-receptor agonists
These compounds imitate growth hormone–releasing hormone, or GHRH, which is naturally produced by the hypothalamus.
Examples studied include:
- Tesamorelin
- Sermorelin
- Modified GRF compounds such as CJC‑1295
They bind to the GHRH receptor on pituitary somatotroph cells, stimulating GH synthesis and release.
Tesamorelin is the clearest clinically established example. It is FDA-approved specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss, bodybuilding or anti-aging treatment. FDA prescribing information
Ghrelin-receptor agonists
These activate the growth hormone secretagogue receptor, usually identified as GHS‑R1a. This is the receptor involved in ghrelin signaling.
Research examples include:
- GHRP‑2
- GHRP‑6
- Hexarelin
- Ipamorelin
- Ibutamoren, also called MK‑677, which is orally active and is not itself a peptide
These compounds can stimulate GH through a pathway distinct from the GHRH receptor. Ghrelin-receptor signaling also interacts with appetite, energy balance, glucose regulation and gastrointestinal function; therefore, its effects are not necessarily limited to GH release. Review of ghrelin and GH regulation
2. What is an analog?
An analog is a modified version of a naturally occurring molecule. It is engineered to retain a desired biological action while potentially changing stability, potency, half-life or receptor selectivity.
“Analog” describes the compound’s structural relationship—not necessarily its mechanism.
For example:
- Tesamorelin is a stabilized GHRH analog and also functions as a GH secretagogue.
- Sermorelin is an analog of the active portion of natural GHRH.
- Somatropin is recombinant human GH. It acts as hormone replacement rather than telling the pituitary to release more GH.
- Long-acting GH products are modified GH analogs designed to extend exposure.
Therefore, secretagogue and analog are not opposites. A compound can be both.
3. The key differences
| Feature | GHRH analogs | Ghrelin-receptor secretagogues | Recombinant GH |
| Primary target | GHRH receptor | GHS‑R1a receptor | GH receptors in body tissues |
| Main action | Stimulates pituitary GH release | Stimulates pituitary GH release through ghrelin signaling | Directly supplies GH activity |
| Requires functioning pituitary | Generally yes | Generally yes | No |
| GH pattern | May preserve some pulsatility | Produces stimulus-related pulses | Depends on administered exposure |
| Effect on IGF‑1 | Indirect, through endogenous GH | Indirect, through endogenous GH | Direct downstream stimulation |
| Additional effects | Primarily GH-axis signaling | May affect appetite and metabolism | Broad systemic GH effects |
| Regulatory status | Varies by compound and indication | Most remain investigational | Approved for defined GH-deficiency and growth disorders |
4. Why the body’s feedback system matters
The GH axis is regulated by three principal signals:
- GHRH: encourages GH release.
- Somatostatin: suppresses GH release.
- Ghrelin signaling: promotes GH release and interacts with metabolic and appetite pathways.
GH and IGF‑1 also participate in negative feedback. As the downstream signal rises, the hypothalamus and pituitary receive signals to reduce further output.
Secretagogues operate within portions of this regulatory system. Recombinant GH largely bypasses the hypothalamic release step by introducing GH activity directly into circulation.
However, calling secretagogues “self-limiting” or inherently safer would be an overstatement. Strong or prolonged stimulation can still produce excessive IGF‑1 exposure and metabolic or fluid-retention effects.
5. What researchers actually measure
Researchers do not establish effectiveness simply by showing that GH increased once. They evaluate several levels of evidence.
Immediate hormone response
After administering a test compound, researchers may collect blood repeatedly over several hours and measure:
- GH peak concentration
- Time to peak
- Area under the concentration-time curve
- Number of detectable GH pulses
- Pulse amplitude
- Pulse duration
- Total estimated GH secretion
- Baseline or non-pulsatile secretion
- GH clearance or disappearance rate
Specialized deconvolution analysis can estimate the timing and magnitude of secretory events from serial GH measurements. Research on GH pulse measurement
Longer-term pathway activity
Researchers commonly measure:
- IGF‑1
- Age- and sex-adjusted IGF‑1 standard deviation score
- IGF-binding protein 3, or IGFBP‑3
- Fasting GH or integrated overnight GH in selected protocols
IGF‑1 is more stable than GH and provides a better indication of sustained GH-axis activity. It still does not prove that a person experienced a meaningful clinical benefit.
Metabolic outcomes
Because GH affects glucose, fat and protein metabolism, researchers examine:
- Fasting glucose
- Fasting insulin
- HbA1c
- Insulin sensitivity
- Oral glucose-tolerance responses
- Triglycerides and cholesterol
- Free-fatty-acid mobilization
- Resting energy expenditure
An increase in GH or IGF‑1 can coexist with worsening insulin sensitivity, so hormone elevation alone should not be described as universally beneficial.
Body-composition outcomes
Depending on the study, researchers may use:
- MRI or CT measurement of visceral adipose tissue
- DEXA measurement of fat and lean mass
- Waist circumference
- Total body weight
- Muscle cross-sectional area
- Bone mineral density
A rise in “lean mass” must be interpreted carefully because fluid retention can sometimes contribute to that measurement. It does not automatically equal new functional muscle tissue.
Functional outcomes
The strongest research asks whether measurable hormone changes translate into improvements such as:
- Muscle strength
- Physical performance
- Exercise capacity
- Recovery from injury or illness
- Sleep quality
- Patient-reported quality of life
- Disease-specific clinical outcomes
These outcomes are more meaningful than changes in GH or IGF‑1 alone.
6. Major variables that affect the results
GH research is particularly sensitive to:
- Age
- Biological sex
- Body-fat level
- Sleep quality and timing
- Fasting versus fed state
- Exercise
- Stress and acute illness
- Glucose levels
- Estrogen and testosterone status
- Baseline pituitary function
- Kidney and liver function
- Time of sample collection
- Laboratory assay methodology
Obesity, aging and poor sleep can reduce spontaneous GH secretion. This means two people receiving the same experimental stimulus may show very different responses.
7. Safety signals researchers monitor
Important surveillance measurements include:
- IGF‑1 elevation
- Fasting glucose and HbA1c
- Edema and fluid retention
- Joint and muscle discomfort
- Carpal-tunnel-type symptoms
- Blood pressure
- Headache or visual symptoms
- Injection-site reactions
- Thyroid and adrenal function when clinically relevant
- Sleep-apnea symptoms
- Evidence of active or recurrent malignancy
The FDA label for tesamorelin specifically warns about elevated IGF‑1, glucose intolerance or diabetes, fluid retention, hypersensitivity, active malignancy and use during acute critical illness. Long-term cardiovascular safety for its approved population has not been established. FDA prescribing information
8. What the evidence does—and does not—prove
A compound can:
- Bind the intended receptor.
- Produce a measurable GH pulse.
- Raise IGF‑1.
- Alter body composition.
Yet still lack convincing evidence that it improves long-term health, physical function, injury recovery or lifespan.
This distinction is especially important for investigational compounds marketed with “anti-aging,” muscle-building or recovery claims. Biochemical activity is not the same as demonstrated clinical benefit.
Professional summary
Growth hormone secretagogues stimulate the pituitary to release endogenous GH. GHRH analogs work through the GHRH receptor, while GHRP-type compounds work primarily through the ghrelin receptor. Recombinant GH differs because it directly supplies GH activity rather than stimulating its release.
Researchers assess these compounds through serial GH measurements, GH pulse analysis, IGF‑1 and IGFBP‑3 concentrations, metabolic safety markers, body-composition imaging and—most importantly—functional clinical outcomes. A temporary increase in GH or IGF‑1 shows pathway activation, but it does not by itself establish safety, therapeutic effectiveness or longevity benefit.